Gilead Sciences has raised its full-year product sales guidance to $31 billion to $31.3 billion, up from the previous range of $30.1 billion to $30.4 billion. The increase is driven by continued strength in its HIV portfolio, which remains a core revenue driver for the biopharmaceutical company. The updated outlook reflects robust demand and successful commercial execution across its antiviral treatments.
The company’s performance underscores the ongoing importance of its HIV franchise, despite broader challenges in the pharmaceutical sector. Gilead has maintained growth through product innovation and market expansion, particularly in long-acting injectables and combination therapies. The revised forecast signals confidence in near-term sales momentum.
Investors are watching closely as Gilead balances R&D investments with shareholder returns. The new guidance range suggests operational resilience and effective portfolio management in a competitive market.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing